Purpose To examine the effect of farnesoid X receptor (FXR) activation by its synthetic agonist, 3-[2- -5-(1-methylethyl)-4-isoxazolyl]methoxy]phenyl] ethenyl]benzoic acid (GW4064) on diet-induced obesity and hepatic steatosis. Methods Fifteen week-old C57BL/6 mice fed with high-fat diet (HFD) or high-fat, high-cholesterol diet were treated by twice weekly injection of GW4064 (50 mg/kg) intraperitoneally or DMSO (carrier solution) for 6 weeks. Body weight, body composition and food intake were monitored weekly. Serum glucose and insulin levels and lipid content in the liver were measured at the end of study. Additionally, genes involved in lipogenesis, gluconeogenesis and inflammation were analyzed by real time PCR. CD36 protein level was detected by western blot. Results Activation of FXR by GW4064 suppressed weight gain in C57BL/6 mice fed with either HFD or high-fat and highcholesterol diet. GW4064 treatment of mice significantly repressed diet-induced hepatic steatosis as evidenced by lower triglyceride and free fatty acid level in the liver. Analysis of genes involved in lipid metabolism showed GW4064 markedly reduced lipid transporter Cd36 gene expression without affecting expression of genes that are directly involved in lipogenesis. GW4064 treatment attenuated hepatic inflammation while having no effect on white adipose tissue. In addition, activation of FXR by GW4064 avoided diet-induced hyperinsulinemia and hyperglycemia through decreasing the transcript levels of phosphoenolpyruvate carboxykinase (Pepck) and glucose-6-phosphatase (G6pase), two key enzymes in gluconeogenesis. Conclusions The results verify the important function of FXR in diet-induced obesity and suggest that FXR agonists are promising therapeutic agents for obesity-associated metabolic disorders.
INTRODUCTION
Farnesoid X receptor (FXR, also known as bile acid receptor or BAR) is a ligand-activated receptor belonging to the nuclear receptor superfamily. It is highly expressed in the liver, intestine, kidney and adrenal gland and is expressed in the heart and adipose tissue as well (1) . Bile acids are believed to be the endogenous ligands for FXR (2, 3) . FXR has a critical role in maintaining bile acid and cholesterol homeostasis through controlling hepatic cholesterol catabolism, bile acid synthesis and intestinal absorption (4) (5) (6) .
In recent years, the role of FXR in lipid and glucose metabolism has been explored. FXR activation lowered plasma and liver triglyceride by enhancing plasma triglyceride clearance (7, 8) and repressing sterol regulatory element-binding protein (SREBP) 1c-mediated hepatic lipogenesis (9) . Elevated serum glucose and impaired insulin tolerance have been detected in FXR-null mice fed with normal diet (10) . In Zucker (fa/fa) obese rats, ob/ob mice and diabetic db/db mice, activation of FXR improved lipid metabolism and insulin sensitivity (11) (12) (13) , suggesting that activation of FXR by agonist could be an attractive pharmacological strategy for managing dietinduced obesity and obesity-associated complications. By contrast, more recent studies using FXR knockout mice show that FXR deficiency protected mice from high-fat diet-induced obesity and improved glucose homeostasis (14, 15) .
In this study, we examined the potent effects of chronic activation of FXR by its agonist GW4064 on protection of mice from development of high-fat die-induced obesity and insulin resistance. We also investigated the possible role of GW4064 in blocking diet-induced hepatic steatosis. Finally, we tested the direct effects of GW4064 on expression of genes responsible for maintaining metabolic homeostasis. Our data demonstrate that FXR activation suppresses diet-induced hepatic steatosis and insulin resistance by suppressing expression of fatty acid transporter CD36 gene.
MATERIALS AND METHODS

Materials
GW4064 was synthesized according to a previous report (16) . Oleic acid was purchased from Sigma-Aldrich (St. Louis, MO). Fatty acid-free bovine serum albumin (BSA) was obtained from ICN Biochemicals, (Cleveland, OH). The RNeasy Tissue kit was from Qiagen (Valencia, CA). The SuperScript® III First-Strand Synthesis System was purchased from Invitrogen (Carlsbad, CA). Real-time PCR reagents were acquired from Applied Biosystems (Foster City, CA). An antibody against CD36 was purchased from Thermo Scientific (Rockford, IL). Pierce ECL Western Blotting Substrate was purchased from Thermo Scientific (Rockford, IL). Insulin assay kit was obtained from Crystal Chem (Downers Grove, IL). Oil Red O solution was obtained from Electron Microscopy Science (Hatfield PA). Infinity™ Triglycerides kit was purchased from Fisher Diagnostics (Middletown, VA), total cholesterol assay kit was from Genzyme Diagnostics (Charlottetown, PE Canada) and NEFA-HR assay kits for free fatty acid was from Wako Bioproducts (Richmond, VA). A glucometer and test strips were purchased from LifeScan (Milpitas, CA). High-fat diet (60% kJ/fat, 20% kJ/carbohydrate, 20% kJ/protein) with/without additional 0.2% cholesterol was purchased from Bio-serv (Frenchtown, NJ). C57BL/6 mice were purchased from Charles River (Wilmington, MA).
Animals and Treatment
All procedures performed on mice were approved by the Institutional Animal Care and Use Committee at the University of Georgia, Athens, Georgia. Fifteen-week-old male C57BL/6 mice were fed a high-fat diet with or without additional 0.2% cholesterol and received twice weekly injections of GW4064 (50 mg/kg, intra-peritoneal) or carrier solution [dimethyl sulfoxide (DMSO)] for 6 weeks. Animals were weighed weekly and their body composition was determined using EchoMRI-100™ from Echo Medical Systems (Houston, TX).
Cell Culture
Mouse liver cells (BNL CL.2) were purchased from American Type Culture Collection (Manassas, VA) and maintained in a humidified incubator under 5% CO 2 at 37°C in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. When cells were divided into six-well plates and reached∼90% confluence, sub-confluent cells were washed three times with phosphate buffered saline (PBS) and replaced with serum-free DMEM supplemented with 1% fatty acid-free BSA. Oleic acid (final concentration 500 μM) and GW4064 at various concentrations were added and incubated for 24 h. Cells were then fixed with 4% formaldehyde for Oil Red O staining or harvested for protein and western blot analysis.
Histochemical Analysis
After mice were sacrificed, the liver and white and brown adipose tissues were collected, fixed in 10% formalin, embedded in paraffin, and sectioned at a thickness of 5 μm. Hematoxylin and eosin (H&E) staining were performed. Frozen sections (9 μm) were stained with 0.2% Oil Red O in 60% of 2-propanol for 10 min and washed three times with PBS. Microscopic examination was performed, and photographs were taken under a regular light microscope.
Lipid Extraction and Analysis
Liver tissues were homogenized in PBS and protein concentration was determined. Total lipids in 300 μl of homogenate were extracted by addition of 5 ml of chloroform-methanol (2:1, vol/vol) mixture. An aliquot of the organic phase was evaporated to dry and resolved in 2% Triton X-100. Hepatic cholesterol, triglyceride, and free fatty acid assays were performed according to the manufacturer's instructions.
Analysis of Serum Lipids and Insulin Levels
Blood samples were collected from fasted mice. Cholesterol, triglyceride, free fatty acid and insulin levels in the plasma were measured using commercial assay kits according to the manufacturer's instructions.
Glucose Tolerance Test (GTT)
For GTT, mice were injected intraperitoneally with glucose at 2 g/kg body weight after fasting overnight. Blood samples were taken at varying time points and glucose concentrations were measured using a glucometer.
Gene Expression Analysis by Real Time PCR
Total RNA was isolated from the mouse liver and white and brown adipose tissues using an RNeasy kit. Two μg of total RNA were used for the first strand cDNA synthesis, as recommended by the manufacturer (Invitrogen, Carlsbad, CA). Real time PCR (RT-PCR) was performed using SYBR Green as an indicator on the ABI StepOne Plus Real-Time PCR system. The final reaction mixture contained 20 ng of cDNA, 250 nM of each primer, 10 μl of 2× SYBR Green PCR Master, and RNase-free water to complete the reaction mixture volume to 20 μl. PCR was carried out for 40 cycles at 95°C for 15 s and 60°C for 1 min. Fluorescence was read during the reaction, allowing a continuous monitoring of the amount of PCR product. The data were normalized to internal control GAPDH mRNA. The primer sequences employed are summarized in Table I .
Western Blot Analysis
Fifty micrograms of total proteins were separated on 10% SDS-PAGE gels and transferred onto a polyvinylidene difluoride membrane using a Bio-Rad Mini-Blot transfer apparatus. Membranes were blocked in Trisbuffered solution (TBS) containing 5% nonfat dried milk for 1 h. The immunoblotting was performed at 4°C overnight with shaking using antibodies against CD36 at 1:1000 dilution. After being washed, the membrane was incubated in a 1:3,000 dilution of a secondary antibody (goat anti-rabbit IgG-HRP conjugate) at room temperature for 1 h in Tris-buffered saline containing 0.5% of Tween-20. Protein bands were visualized using Pierce ECL Western Blotting Substrate.
Statistical Analysis
Statistical analysis was performed by one-way ANOVA. All data are reported as mean±standard deviation (SD) with statistical significance set at P<0.05.
RESULTS
FXR Agonist GW4064 Suppresses Diet-Induced Obesity in Mice
To investigate the role of FXR activation in diet-induced obesity, 15-week-old male C57BL/6 mice were fed a highfat diet (HFD) with or without 0.2% cholesterol while being treated with either DMSO (vehicle) or GW4064 (50 mg/kg, twice weekly) for 6 weeks. As expected, HFD feeding induced a progressive increase in body weight (Fig. 1a) . GW4064 significantly attenuated the increase in weight gain. A statistical difference was evidenced as early as the first 3 weeks of HFD-feeding and the difference in body weight was 6.5 g between treated and control animals at the end of experiment. Considering the function of FXR in cholesterol metabolism, we also assessed whether FXR activation has different effects on mice fed with extra dietary cholesterol (HFD-Chol). As shown in Fig. 1b , GW4064 also suppressed the gain of body weight when 0.2% cholesterol was included in the HFD. There was also 5.2 g difference in body weight between GW4064-treated and control animals at the end of 6-week treatment. Difference in body weight between DMSO-and GW4064-treated groups was due to a slight, but significantly reduction in fat and lean mass (Fig. 1c, d ), while the food intake was unchanged among 
the groups as shown in Fig. 1e and f. In addition, hematoxylin and eosin (H&E) staining showed no obvious difference in adipocyte size in both WAT and BAT (Fig. 1g, h ) between control and GW4064-treated animals. These results suggest that GW4064 does not block but significantly suppressed the gain of body weight in animals on HFD with or without inclusion of extra cholesterol.
GW4064 Represses Hepatic Steatosis and Plasma Lipid Level in HFD-fed Mice
Hepatic steatosis is frequently observed in obesity (17) . To investigate whether activation of FXR by GW4064 prevents hepatic lipid accumulation, liver weight was measured after mice were sacrificed at the end of treatment. As shown in Fig. 2a and b, the average liver weight of control animals on HFD is 1.6 g compared to about 2.1 g for animals fed with HFD-Chol. Importantly, with GW4064 treatment, the average liver weight from both groups is about 1.2 g, and 1.3 g, 0.4 and 0.8 g less than that of controls with or without extra cholesterol included, respectively. H&E staining of liver sections shows extensive vacuolation in control animals ( Fig. 2c and e) but not in those treated ( Fig. 2d and f) with GW4064. Oil Red O-staining confirms massive presence of fatty components in liver sections in animals on HFD (Fig. 2g ) and HFD-Chol (Fig. 2i) . In contrast, Oil Red O staining of liver sections displayed significantly less fat accumulation in GW4064 treated groups (Fig. 2h, j) . Consistent with the results from the liver sections, treatment of mice with GW4064 significantly reduced hepatic triglyceride (Fig. 3a) and free fatty acid (Fig. 3b ) levels in animals fed with HFD and HFD-Chol. As expected, the overall cholesterol level in the liver of animals fed with HFD-Chol is higher than that of animals on regular HFD (Fig. 3c) . GW4064 treatment also slightly brought down the cholesterol level in both cases.
The effects of GW4064 on serum concentration of triglyceride, free fatty acids and cholesterol were also examined. Results in Fig. 3d and f show significantly lower concentrations of triglyceride and cholesterol in GW4064 treated animals. There is no statistical difference in serum concentration of free fatty acids in animals with or without GW4064 treatment (Fig. 3e) . Taken together, these data demonstrate that activation of FXR by GW4064 markedly reduces hepatic lipid levels and improves the plasma lipid profile of mice on HFD.
GW4064 Attenuated Diet-Induced Hepatic Inflammation
It is well known that obesity is a chronic inflammatory disease. Dietary cholesterol is an important risk factor for liver inflammation (18, 19) . Therefore, we examined whether the protective effect of GW4064 on the liver involves suppression of hepatic inflammation. Results in Fig. 4a showed elevated expression by 1.8-2.2 folds of macrophage marker genes including F4/80, Cd68, Cd11c, and Cd11b in mice fed HFDChol compared to those fed regular HFD. Compared to the HFD-fed group, cholesterol also enhanced gene expression of chemokine monocyte chemo-attractant protein-1 (Mcp-1) by 3.7-fold and pro-inflammatory factor Il-1β and TNFα by 1.8-and 4.4-fold, respectively (Fig. 4b) . GW4064 treatment significantly suppressed the diet-induced increase of inflammatory mediators, as evidenced by reduced macrophage markers and decreased inflammatory factor levels in liver. It is noted that GW4064 treatment did not affect mRNA levels of the same class of genes in white adipose tissue (WAT) (Fig. 4c, d ), indicating GW4064-activated FXR did not block macrophage infiltration into WAT. These data suggest that GW4064 treatment significantly reduces hepatic inflammation associated with HFD and HFD-Chol feeding.
GW4064 Prevented Lipid Accumulation in Liver Through Reducing CD36 Expression
To determine how GW4064 treatment reduces excess lipid accumulation in the liver, the expression profiles of genes that are involved in lipid metabolism were analyzed. As shown in Fig. 5a , GW4064 failed to inhibit lipogenesis in diet-induced obese mice, as evidenced by unchanged expression of sterol regulatory element-binding protein 1c (Srebp-1c), acetyl-CoA carboxylase1 (Acc1) and even upregulated stearoyl CoA desaturase 1(Scd-1). The mRNA level of peroxisome proliferator-activated receptor alpha (Ppar-α) also did not significantly change. However, GW4064 markedly reduced the mRNA level of Cd36 by 37% in HFDfed and by 60% in HFD-Chol-fed animals. Western blot analysis of liver extract (Fig. 5b) showed that CD36 protein level was also decreased in GW4064-treated animals.
To ascertain that a decrease of CD36 expression contributes to the reduction of hepatic lipid accumulation by GW4064 treatment, a similar in vitro study was performed in a mouse liver cell line (BNL Cl.2). As shown in Fig. 6a , incubation of cells with oleic acid (500 μM) clearly increased the number of lipid droplets compared to the DMSO-treated control group. Treatment with different concentrations of GW4064 reduced the lipid accumulation in the cells. Concordantly, GW4064 treatment significantly repressed oleic acidinduced CD36 protein levels in a dose-dependent manner (Fig. 6b) . Taken together, these data indicate that prevention of hepatic lipid accumulation is likely due to an inhibition of Cd36 expression by long-term GW4064 treatment.
Improvement of Diet-Induced Hyperinsulinemia and Hyperglycemia by GW4064 Treatment
Obesity is a strong risk factor for insulin resistance, a characteristic of type-2 diabetes. We then investigated whether FXR activation by GW4064 would affect glucose homeostasis. Compared to HFD-fed animals, inclusion of extra dietary cholesterol in HFD induced higher plasma glucose levels (235±15 vs. 195±21; p=0.02). However, glucose tolerance tests (Fig. 7a, c) and calculated area under the curve (AUC) (Fig. 7b, d) showed a much quicker clearance rate of intraperitoneally injected glucose in GW4064-treated animals, indicating activation of FXR by GW4064 could maintain plasma glucose level. GW4064 also ameliorated diet-induced hyperinsulinemia (Fig. 7e) and similar patterns were obtained by HOMA-IR (Fig. 7f ). These results demonstrate that GW4064 treatment prevents the progression of insulin resistance in animals on HFD with or without extra cholesterol.
To investigate how GW4064 treatment maintains glucose levels in animals, we measured the expression of genes involved in hepatic gluconeogenesis after mice were sacrificed. Results in Fig. 7g from real-time PCR revealed that GW4064 treatment significantly lowered the amount of transcript for phosphoenolpyruvate carboxykinase (Pepck) and glucose-6-phosphatase (G6pase), concordant with reduction of diet-induced hyperglycemia and hyperinsulinemia. 
DISCUSSION
The current study demonstrates that activation of FXR by GW4064 reduced weight gain in mice fed a HFD with or without excess cholesterol ( Fig. 1a and b) included. GW4064 treatment significantly curbed HFD-induced hepatic steatosis as evidenced by lower level of triglyceride, free fatty acid and cholesterol in the liver (Figs. 2 and 3a-c) . RT-PCR analysis revealed that GW4064 treatment attenuated hepatic inflammation but had no effect on white adipose tissue (Fig. 4) . GW4064 treatment markedly reduced expression of lipid transporter CD36 (Figs. 5 and 6) without affecting expression of genes directly involved in lipogenesis. In addition, activation of FXR by GW4064 blocked diet-induced hyperinsulinemia and hyperglycemia through decreasing transcription of phosphoenolpyruvate carboxykinase (Pepck) and glucose-6-phosphatase (G6pase), two key enzymes in gluconeogenesis (Fig. 7) . These results provide direct evidence in support that FXR activation can be considered as an effective mean in blocking high fat diet-induced hepatic steatosis and insulin resistance. HFD-Chol was included in the study because FXR is known for its function in cholesterol metabolism, hepatic steatosis and inflammation (18) (19) (20) . With 6-week feeding, extra amounts of cholesterol in HFD did not further increase animal body weight compared to those fed with HFD, suggesting that dietary cholesterol does not play critical role in animal growth when on HFD. However, addition of cholesterol markedly enhanced hepatic steatosis as evidenced by an increase in liver weight and lipid content. HFD-Chol also enhanced hepatic inflammation as evidenced by elevated mRNA level of macrophage markers and pro-inflammatory factors (Fig. 4) . Mice fed a HFD-Chol also had much higher plasma glucose concentrations compared to that of animals fed a HFD. These results suggest that dietary cholesterol has a significant influence on lipid metabolism in the liver.
Results in Figs. 2 and 3 clearly show that GW4064 prevented liver steatosis by reducing hepatic lipid accumulation. In addition, activation of FXR also markedly attenuated mRNA levels of macrophage markers and pro-inflammatory mediators in the liver, in agreement with a previous study using WAY-362450 as a FXR activator in mice fed a methionine and choline-deficient diet (21) . As for the mechanism through which FXR exerts its hypotriglyceridemic effect, the major function of FXR is to inhibit lipogenesis (9) . For example, the study in Zucker (fa/fa) rats fed with standard diet showed FXR agonist 6-ethyl-chenodeoxycholic acid (6E-CDCA) protected agonist hepatic steatosis by inhibiting expression of Srebp-1 and its target gene fatty acid synthase (Fas), the key genes involved in lipogenesis (12) .
CD36 is responsible for the transport of long-chain fatty acids into the adipose and hepatic tissues (22, 23) . Increased hepatic CD36 activity is critical for the development of steatosis in obesity (24) (25) (26) . Results in Fig. 5 show that expression of Cd36 is significantly reduced in GM4064-treated animals at both mRNA and protein level, suggesting that high level of CD36 plays an important role in HFD-induced hepatic steatosis. To provide additional evidence in support of such a possibility, we cultured BNLC1.2 cells in presence of varying amounts of GW4064, and the results in Fig. 6 clearly show that GW4064 concentration used in treatment is reversely proportional to the lipid levels in cultured cells (Fig. 6a ) and CD36 protein levels (Fig. 6b) in the presence of 500 μM oleic acids. It is likely that GW4064-mediated inhibition of hepatic steatosis is achieved by reducing CD36 activity at mRNA and protein levels. Concordant with our results, other groups also reported that GW4064 significantly reverted HIV p17 protein-induced Cd36 mRNA level in THP-1 macrophages (27) and treatment with other FXR agonist INT-747 resulted in a robust reduction of CD36 expression on circulating macrophages in ApoE −/− mice (28). In addition, recent studies revealed that HFD significantly induced CD36 expression in the liver (26, 29) and enhanced adipose tissue and liver inflammation. CD36 knockout mice showed a repression in hepatic inflammation (30, 31) . Therefore, reduction of diet-induced CD36 expression by GW4064 may also help to ameliorate hepatic inflammation.
It is known that FXR activation affects lipid metabolism at different levels. For example, GW4064 inhibits lipogenesis by suppressing expression of Srebp1c and its target genes in mice fed a regular chow (9, 11) . It has also been shown that FXR −/− mice have normal or reduced hepatic Srebp1c expression (32, 33) . Activation of FXR was found to be able to enhance PPARα activity and increase triglyceride clearance (34) . In addition, the effect of GW4064 treatment is time dependent. Cholic acid-induced FXR activation ameliorates expression of genes involving in lipogenesis in C57BL/6 mice 1 day after the GW4064 treatment, but the inhibitory effect was not seen after treatment for 7 days (9). The results summarized in this study suggest that activation of FXR by GW4064 in mice fed a high-fat diet blocks liver steatosis by suppressing expression of CD36 gene encoding fatty acid transporter. GW4064 treatment prevented HFD-induced hyperglycermia and hyperinsulinma (Fig. 7) . Such activity is co-related to a lower mRNA level of Pepck and G6pase, two key genes in gluconeogenesis, in agreement with previous report in db/db mice (11) . It remains to be elucidated how FXR activation improves insulin sensitivity. It is conceivable that FXR exerts an indirect effect on insulin sensitization by decreasing lipid levels as FXR is not expressed in skeletal muscle and at very low level in white adipose tissue. Since lipotoxicity could impair insulin signaling at the peripheral level (35) , reduction of hepatic and plasma lipid levels may contribute to improving insulin sensitivity.
The detailed mechanism for GM4064 effect on animals fed a high fat diet remains to be elucidated. We believe that GW4064-activated FXR may suppress CD36 expression by inhibiting liver X receptor (LXR) activation. It is known that FXR and LXR, both serving as intracellular sensors, often oppose each other's action in order to maintain a balance for cholesterol and fat metabolism (36) . It has been shown, using chenodeoxycholic acid as FXR activator, that activated FXR induces small heterodimer partner (SHP) gene expression, decreases scavenger receptor class B, type I (SR-B1) gene expression, and inhibits LXR and liver receptor homolog-1 (LRH-1) activation (37) . Since Cd36 is a target gene of LXR (38) , it is highly possible that GW4064-activated FXR suppresses Cd36 expression by inhibiting LXR activation.
In addition, Scd-1 is generally considered as pro-lipogenic gene encoding SCD1 serving as a rate-limiting enzyme for converting saturated fatty acids to monounsaturated fatty acids. Recent study showed that enhanced SCD1 activity in liver is associated with low fat content in healthy subjects under a lipogenic diet (39) . Increase in Scd-1 mRNA level (Fig. 5a) suggests that chronic activation of FXR by GW4064 in mice fed a high fat diet could reduce the level of saturated fatty acids, and thereby, preventing deleterious lipotoxicity induced by the saturated fatty acids.
In summary, we demonstrate in the current study that GW4064-mediated FXR activation ameliorates diet-induced obesity, suppresses hepatic lipid accumulation, and maintains glucose and lipid homeostasis in C57BL/6 mice. These results suggest that the pharmacological activation of FXR represents a promising therapeutic strategy for treatment of obesityassociated liver steatosis.
